Margin collapse in soft quarter; backward integration bet intact but timing uncertain
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 5/10
Grade C
FY27 EBITDA guide of ₹1,500-1,600 Cr (prior call) is on track to miss by ₹1,000+ Cr. Only one quarter in; trajectory is materially off.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Volume growth (38% revenue, 32% MW) demonstrates market share gains and execution on Gangaikondan ramp, but Q1 margin collapse (OPM 8.1%, NPM 1.3%, PAT -85% YoY) signals structural oversupply and cost pass-through failure. Prior FY27 EBITDA guidance of ₹1,500-1,600 Cr is implicitly abandoned—Q1 run-rate annualizes to ~₹504 Cr, 66% short. Backward integration thesis (cell Q4 FY27, wafer/ingot FY29) is credible long-term but offers no near-term relief; management deferred guidance pending H1 clarity. Key risk: if non-DCR margins remain under 8% through FY27, full-year PAT could undershoot by 40%+.
₹1563.1 Cr
Revenue · +37.9% YoY₹19.8 Cr
Reported PAT · −85.2% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Highest ever quarterly volume, 1,006 MW, up 32% YoY
METDelivered 1,006 MW; 32% YoY growth confirmed. But volume growth masks margin collapse.
Revenue grew 38% year-on-year
METDelivered ₹1,563.1 Cr, up 37.9% YoY. Claim of 38% matches delivered result.
EBITDA margins to expand post cell-line commissioning due to integrated platform
MISSQ1 EBITDA 8.1%, well below historical 12-16% range. Backward integration thesis unproven; commissioning Q4 FY27 still 8+ months away.
Cost escalation primarily input-price driven and transitory
OVERSTATED₹1.86/Wp cost rise. War-driven metal/EVA inflation is real but non-DCR oversupply prevents pass-through on BORM (35-47% of cost). Structural, not just transitory.
DCR mix to grow manifold, lifting margins
PartialOnly 76 MW DCR in Q1 (7.5% of 1,006 MW volume). Management expects 2-2.5x quarterly growth, but base is too small to materially impact FY27 EBITDA yet.
Earnings quality
What changed since the last call
EBITDA margin guidance withdrawn
DowngradePrior FY27 guide: ₹1,500-1,600 Cr EBITDA. Q1 delivered ₹126 Cr (8.1%), annualizes to ~₹504 Cr. Management deferred guidance to H1; no revised target given. Implicit 60%+ cut vs prior.
DCR business is nascent, not core
DowngradeCalled 76 MW DCR in Q1 vs 1,006 MW total = 7.5%. Expected to grow 2-2.5x quarterly, but base too small to move needle in FY27. Margin benefit pushed to FY28.
Cost pass-through failed on BORM
Downgrade88% of order book has escalation clauses, but only for cell costs. BORM (35% metals, 12% EVA, freight) cannot be passed due to oversupply. ₹1.86/Wp cost rise is structural this quarter.
Capex phasing brought forward
UpgradeWafer-ingot capacity increased 6 GW → 9 GW; cell plant on track Q4 FY27 (prior was Dec → March). Module facility (Gangaikondan) first unit on June 29 per promise. Execution discipline maintained.
Order book composition shifting toward mid-market
Neutral7.9 GW order book now includes larger mid-market, distribution channels (119+ distributors, 757 dealers). Pricing ₹0.50-1.50/Wp premium over large accounts. Mix benefit emerging but unproven at scale.
The Q&A
Analysts pressed hard on margin recovery, cost escalation pass-through, and ALMM policy impact. Management was candid on BORM escalation (not contractually protected) and acknowledged competitive oversupply preventing price realization. Sameer defended long-term strategy (backward integration) but was defensive on peer margin comparisons. Reiterated 'wait 90 days' refrain 6+ times, signaling real uncertainty on H1 outlook. No evasion on major questions, but clear reluctance to commit to guidance.
Margin compression, cost pass-through — Deepak Purswani, Svan Investments
AnsweredMSA escalation clauses cover only cell costs, not BORM (balance of raw materials). Metals, EVA, freight inflation in BORM was not passed due to competition. Even cell cost escalation was partially absorbed due to oversupply.
DCR margin premium vs non-DCR — Pravin Sahay, PL Capital
PartialDCR delivers more margin than non-DCR. Cannot quantify separately yet due to small Q1 sample. Serious volumes will flow in coming quarters, allowing better clarity.
Order book executability — Deepak Purswani, Svan Investments
DodgedCapacity of 15.5 GW can deliver 9-9.5 GW for full year. Exact executability depends on customer decisions around ALMM 2 and infrastructure clarity. Allow one more quarter for clarity.
Peer margin comparison — Bala Murali Krishna, Oman Investment Advisors
PartialCaptive cell ramp focus. Peers with in-house cells benefit from cell margins. We don't have cells until Q4 FY27. Strategy shift to retail channels carries temporary margin pressure.
When do margins normalize — Vishant Shah, Adani Properties
DodgedOnce cell line commissioned, margins will expand because DCR captures cell margins. True peer comparison only possible then. Different players at different cell commissioning stages.
Cell manufacturing cost and import pricing — Karan Gupta, Asit C Mehta Investment
AnsweredOur cell lines are best-in-class, so cost will be among India's best. Chinese cells 4 cents/W landed price + 27.5% BCD = ~5.1 cents/W procurement cost. DCR pricing very different from non-DCR.
FY27 EBITDA guidance update — Bhagwat, Prosperity Wealth Management
DodgedLet us reconnect in mid-year with clarity on DCR pricing, distribution penetration, and ALMM 2 policy. Margins broadly in this range but could improve.
Volume and policy impact — Mohammad Ansari, Taha Capital Management
AnsweredPolicy changes made customers tentative. Grandfathered projects facing price volatility and infrastructure delays. Not updating guidance now; waiting for clarity to emerge.
Backward integration differentiation — Ritesh Abbi, Kingsman Wealth Fund
AnsweredFour pillars: (1) Best-in-class products (20-year legacy), (2) Integrated world-class manufacturing (cell, wafer, module at Gangaikondan), (3) Cost-efficient structure, (4) Diversified customer base (large, mid-market, distribution). This mix will set us apart.
ALMM policy and non-DCR demand — Karan Gupta, Asit C Mehta Investment
AnsweredGrandfather projects: ~80 GW for non-DCR. ALMM 2 extension now allows C&I to also shift to non-DCR, topping up eligible volume. C&I market is 15 GW/year; 6-7 GW rooftop, rest ground-mount open access.
Guidance
FY27 capacity delivery: 9-9.5 GW for full year if market absorbs
Medium15.5 GW total capacity (Gangaikondan 6 GW module fully operational Q2; Vallam legacy + ramp). Actual volume depends on order book timing and customer decision-making around ALMM 2 / infrastructure clarity.
C&I demand: 15 GW/year market; policy clarity on ALMM 2 extension (deferred to Dec 31) expected to unlock ~80 GW grandfather + new non-DCR orders
MediumFresh utility tenders post-Aug 2025 threshold total 35-40 GW, but execution 18-24 months out. H1 FY28 procurement expected.
FY27 EBITDA margin: NOT reaffirmed; management deferred to H1 FY27 earnings (re-baseline)
LowPrior FY27 guidance ₹1,500-1,600 Cr EBITDA is implicitly cut. Q1 run-rate (~₹504 Cr) 66% below prior. Margin recovery dependent on DCR ramp, cost normalization, and capex margins.
Non-DCR margins to remain under pressure through Q2-Q3; DCR mix uplift expected Q2 onwards
MediumCost pressures (metals, EVA) continuing. DCR mix to grow 2-2.5x quarterly starting Q2, but small base limits impact. Management expects 'rationalization' in non-DCR margins if war-driven costs ease.
Once cell line commissioned Q4 FY27, DCR margins to expand due to in-house cell capture (FY28+)
MediumNo specific margin target given. Backward integration margin benefit unproven; depends on cell cost competitiveness vs ₹4 cents/W Chinese import + 27.5% BCD.
FY27: ~₹5,000 Cr capex (80% module, 20% cell); FY28: Similar ₹5,000 Cr; FY29: BESS cell plant (7.5 GWh) and wafer-ingot completion
High₹500 Cr deployed in Q1 FY27. Full capex plan: 6 GW module facility ₹fully funded, 9 GW cell plant ₹~3,000 Cr, 9 GW wafer-ingot ₹5,600 Cr (phased), 15 GWh BESS ₹700-800 Cr (2-year build, phase 1 assembly Q1 FY28, cell Q4 FY29).
Debt-to-equity phasing: 75:25 operational, landing at 70:30 post-scheme payouts
HighNo debt drawn yet; drawdown sequenced to project milestones. Financial closure for debt in process. Capex will be major debt-funded (₹7-7.5 Cr over 2 years).
Risks the call surfaced
Margin compression (structural)
High210 GW national capacity, 45-50 GW demand; 88% of order book MSAs only escalate cell, not BORM (35% metals, 12% EVA). War-driven inflation unpassable. Q1 margin 8.1% vs historical 12-16%; recovery path uncertain.
ALMM 2 policy execution risk
HighALMM 2 cell mandate implemented June 1, deferred July 18 to Dec 31. Customers held procurement pending clarity. Further deferrals possible if cell capacity lags targets. C&I segment (15 GW/year) still uncertain on DCR vs non-DCR mix (estimate reduced 20-25 GW to 17 GW DCR).
Capex execution and overrun
High₹10,000 Cr capex over FY27-28 on integrated platform (cell, wafer-ingot, BESS). Cell plant Q4 FY27 on track; wafer-ingot ground-breaking next month. Modular design allows phasing, but supply chain delays (equipment, labor) or policy shifts could push timelines and cost overruns.
DCR ramp execution unproven
MediumQ1 DCR volume only 76 MW (7.5% of 1,006 MW total). Management expects 2-2.5x quarterly growth, but base is small and ramp depends on distribution network adoption, policy stability, and pricing discipline. No large-account DCR orders placed yet (management deferring to post-cell commissioning).
Customer decision-making delays
MediumLarge utilities and IPPs citing land acquisition, evacuation clearance, and utility infrastructure challenges as reasons for procurement delays. Grandfather non-DCR projects (80 GW) moving slower than expected. ALMM 2 policy volatility adding to wait-and-see posture.
Management
Score 6/10. Transparent on cost challenges and policy uncertainty; candid that BORM escalation unpassable due to competition. However, repeated 'allow one more quarter' hedges signal lack of near-term visibility. Some defensiveness on peer margin comparisons (justified, but tone less confident than Q4 FY26). Strong: Gangaikondan module on-time June 29, cell plant Q4 FY27 on track, wafer-ingot capacity increased and groundbreaking next month. Capex discipline maintained (₹500 Cr Q1 per plan). Weak: FY27 EBITDA guidance of ₹1,500-1,600 Cr implicitly abandoned (Q1 trajectory annualizes to ~₹504 Cr); prior guidance credibility damaged.
1 · Q2 FY27
ALMM 2 deferment (effective Dec 2026); C&I non-DCR orders expected to resume. Policy clarity could unlock 15 GW/year delayed demand.
2 · Q4 FY27
Cell plant commissioning (9 GW) and wafer-ingot groundbreaking. First cell ramp will begin; margin accretion deferred to FY28.
3 · H1 FY27
Management revisits FY27 EBITDA guidance. Current trajectory suggests 25-35% downward revision vs ₹1,500-1,600 Cr prior guide.
Key risk: if non-DCR margins remain under 8% through FY27, full-year PAT could undershoot by 40%+.
Volume surge masks a profit cliff; guidance quietly shelved
Revenue surged 38% and volumes set a record 1,006 MW, yet net profit crashed 85%. Management has shelved its ₹1,500–1,600 Cr FY27 EBITDA target — Q1's trajectory annualizes to just ₹504 Cr, 66% short of prior guidance.
The headline profit collapse is structural, not transient
On paper, Q1 delivered a record 1,006 MW of modules (up 32% YoY) and ₹1,563 Cr in revenue (up 38% YoY). But net profit fell to just ₹19.8 Cr, down 85% year-on-year. That chasm — volume up, profit down — is the quarter's defining story. The culprit is not a one-time charge or inventory tail-wind; it is a structural margin collapse from 12–16% EBITDA historically to 8.1% this quarter.
+38%
₹1,563 Cr YoY
+32%
1,006 MW YoY
8.1%
vs 12–16% historical
-85%
₹19.8 Cr YoY
The company had guided for FY27 EBITDA of ₹1,500–1,600 Cr just four quarters ago. Q1's run-rate of ₹126 Cr annualizes to approximately ₹504 Cr — a 66% miss. On the call, management deferred any revised full-year EBITDA target to H1 FY27 earnings, citing the need for clarity on DCR pricing, distribution penetration, and the finalization of the ALMM 2 policy (currently deferred to December 2026). That deferral is an implicit acknowledgment that the prior guidance is gone.
Where the margin went
Three factors crushed the quarter:
Unpassable input cost inflation. Metals and EVA prices spiked (war-driven), adding ₹1.86/Wp to module cost. Only cell costs are contractually escalated in 88% of the order book; balance-of-raw-materials (BORM) — metals 35%, EVA 12%, freight — are unprotected. Oversupply in the 210 GW national module market prevented any price recovery.
Inventory cost drag from Q4 FY26. Chinese cell costs spiked in Q4 FY26; higher-cost inventory flowed through P&L in Q1. This will reverse as lower-cost procurement normalizes, but Q1 was distorted by the tail.
Industry oversupply destroying pricing power. With 210 GW of domestic module capacity chasing 45–50 GW of annual demand, no player — Vikram or peers — can pass through cost inflation to large accounts (utilities, IPPs). Even peers with captive cell plants reported only 1–2% margin erosion; Vikram's 50% decline reflects the same oversupply, compounded by the absence of in-house cells until Q4 FY27.
Management claims vs. what holds up
Highest ever quarterly volume, 1,006 MW, up 32% YoY
SupportedDelivered 1,006 MW; 32% YoY growth confirmed. But volume growth masks the margin collapse entirely.
Revenue grew 38% year-on-year
SupportedDelivered ₹1,563 Cr, up 37.9% YoY. The claim of 38% matches.
EBITDA margins to expand post cell-line commissioning due to integrated platform
ContradictedQ1 EBITDA 8.1%, well below 12–16% historical. Backward integration thesis remains unproven; cell commissioning is Q4 FY27, still 8+ months away. No margin accretion before FY28.
Cost escalation primarily input-price driven and transitory
Overstated₹1.86/Wp cost rise is real. War-driven metal and EVA inflation is genuine, but 47% of the bill (BORM) cannot be passed through due to competitive oversupply. This is structural for at least 2–3 quarters, not transitory.
DCR mix to grow manifold, lifting margins
PartialOnly 76 MW DCR in Q1 (7.5% of 1,006 MW total). Management expects 2–2.5x quarterly growth, but base is too small to materially improve FY27 EBITDA. Margin benefit pushed to FY28.
What changed on this call vs. prior guidance
FY27 EBITDA guidance withdrawn. Prior target ₹1,500–1,600 Cr is now effectively abandoned. Q1 run-rate annualizes to ~₹504 Cr — a 66% shortfall. No revised number offered; management deferring to H1 for clarity.
DCR business promoted to cornerstone of margin recovery. Prior call emphasized capex and backward integration as primary levers. Now DCR ramp (currently 76 MW, expected to 2–2.5x quarterly) is the centerpiece for near-term margin lift. But base is too small to move the needle in FY27.
Tone shifted from confident to defensive. CEO repeated 'allow one more quarter for clarity' 6+ times on the call. Management openly acknowledged cost pass-through failure and the structural nature of oversupply. Less a data update, more a credibility reset.
Capex phasing brought forward (positive). Wafer-ingot capacity increased 6 GW → 9 GW; cell plant on track Q4 FY27 (not Dec–Mar as prior guidance). Gangaikondan module facility delivered first unit June 29, on promised date. Execution discipline proven, but capex ₹10,000 Cr over FY27–28 will require levering to 70:30 debt-equity.
Order book composition shifting mid-market and distribution. 7.9 GW order book now includes larger mid-market, distribution channels (119+ distributors, 757 dealers). Pricing ₹0.50–1.50/Wp premium over large accounts. Mix is positive, but unproven at scale and offers no relief to FY27 margins.
Bull-bear ledger
Backward integration thesis is structurally sound. Cell plant (9 GW) on track Q4 FY27; wafer-ingot (9 GW) groundbreaking next month. In-house cells will capture 2–3% margin internally, structurally lifting EBITDA per watt from current ₹1.25/Wp toward historical ₹1.50–2.00/Wp. Ecovadis Platinum rating (top 1% globally) supports global buyer credibility post-integration.
Capex execution proof. Gangaikondan module facility first unit rolled June 29, on promised date. ₹500 Cr deployed Q1 per plan; no cost overruns to date. If this discipline holds through wafer-ingot groundbreaking and cell plant ramp, capex ₹10,000 Cr over FY27–28 is achievable at 70:30 debt-equity.
Order book is intact and large. 7.9 GW non-DCR order book is not shrinking; customer delays are deferring delivery, not cancelling. Distribution and mid-market ramps provide pricing power (₹0.50–1.50/Wp premium vs large accounts) that does not exist in utility segment. Long-term, this mix shift is value-accretive.
Margin collapse is near-term structural, not cyclical recovery. 210 GW national capacity vs 45–50 GW annual demand = 4.7x oversupply. No pricing power until capacity rationalization (industry M&A, bankruptcies) or demand surge (unlikely before FY29). Vikram's 8.1% EBITDA margin matches oversupply reality; peers' 9–10% is not sustainable either.
FY27 margin recovery is mathematically impossible. Q1 set the baseline at 8.1%. DCR (76 MW, 7.5% of volume) would need to grow to 20–25% mix and deliver 15% margin (vs base 8%) to lift full-year EBITDA by 5 percentage points. Current trajectory suggests 8–9% for full year. Cell margin benefit is 12+ months away (Q4 FY27 commissioning, FY28 ramp).
Prior guidance credibility is shattered. ₹1,500–1,600 Cr FY27 EBITDA was a firm prior call. Q1's trajectory (66% miss) and management's deferral of H1 guidance signals a 25–35% downward revision is coming. Investors who acted on prior guidance now face a material credibility reset.
ALMM 2 policy remains a binary uncertainty. Cell mandate has been deferred June 1 → July 18 → Dec 31. Further deferrals would trigger another customer procurement pause. C&I non-DCR demand unlock (estimated 15 GW/year) is now contingent on Dec 31 finalization — not assured.
Capex ₹10,000 Cr over 2 years carries execution risk. Wafer-ingot (₹5,600 Cr), BESS cell plant (₹700–800 Cr), and cell ramp (₹3,000 Cr) are multi-year bets. Delays, cost overruns, or policy shifts could require equity raise or breach 70:30 debt-equity target. High leverage in a commodity cycle is a real risk.
How the street is positioned
The market's verdict on Q1 was swift and harsh. The stock fell 5.53% on day 1 post-result and 7.67% by day 3, confirming that the margin collapse was not priced in. The stock now trades at ₹163.46, down 53.88% from its all-time high of ₹354.4 and well below its 20-day (₹176.66), 50-day (₹190.96), and 200-day (₹221.97) moving averages. The 52-week range of ₹156.06–₹354.4 places the stock just 4.74% above its lows — a harsh repricing for a company that was trading near ATH just months ago.
Institutional flows offer a mixed signal. FII ownership has ticked up 0.43 percentage points quarter-on-quarter to 3.37%, but this is neither a sign of conviction nor a major inflow — it may reflect index rebalancing or value-tracking rather than fundamental re-rating. DII ownership has declined 0.77pp to 4.03%, suggesting domestic institutions are trimming on the guidance miss. Promoter ownership remains steady at 63.01%, offering some comfort that insiders are not dumping despite the result. The RSI at 31.9 is neutral-to-slightly-oversold territory, and volume is increasing — a combination that suggests more capitulation selling may be ahead before a base forms.
The technical picture aligns with the fundamental case: the stock is repricing down to reflect a 66% EBITDA miss on guidance and a 12-month margin recovery timeline (cell commissioning Q4 FY27 → ramp FY28). The 53.88% drawdown from ATH is warranted on a 12-month view but does not yet reflect the durability of the backward integration thesis or the potential for capex-driven long-term value creation. Downside to ₹140–150 is possible if H1 FY27 guidance reset goes further negative (35%+ cut vs prior); upside to ₹220–240 emerges only if cell margin accretion proves +2–3% in early FY28 execution.
Ranked risks (what should concern a holder most)
Margin compression is structural, not transitory
High210 GW capacity vs 45–50 GW demand = 4.7x oversupply. Pricing power absent in large accounts; 88% of order book has cell escalation only, not BORM. Recovery requires industry consolidation or demand surge (2–3 years). FY27–28 margins stuck at 8–9%.
ALMM 2 policy deferral cascades
HighMandate deferred June 1 → July 18 → Dec 31. Further deferrals would pause C&I procurement (15 GW/year market) and derail DCR ramp momentum. If delayed to FY28, FY27 DCR volume stays <500 MW, missing margin recovery targets entirely.
Capex ₹10,000 Cr execution slips cost or timeline
HighWafer-ingot, cell plant, and BESS cell capacity are multi-year bets. Any 12-month delay or ₹1,000+ Cr cost overrun forces equity raise or breach 70:30 debt-equity target. Leverage in a commodity cycle is dangerous; balance-sheet stress could emerge by H2 FY28.
DCR ramp base too small to move FY27 needle
Medium76 MW DCR in Q1 (7.5% of volume). Needs to hit 20–25% mix and 15% margin to lift full-year EBITDA by 5pp. Current trajectory suggests 8–9% full year. No material margin relief until FY28 at earliest.
Customer decision delays (infrastructure, policy) deepen
MediumLarge utilities citing land, evacuation, utility infrastructure challenges. Grandfather projects (80 GW non-DCR book) moving slower than expected. Delays do not cancel orders, only defer timing; but if pushed to H1 FY28, FY27 volume could undershoot by 10–15%.
FY27 guidance credibility already broken
MediumPrior ₹1,500–1,600 Cr EBITDA target is now a credibility scar. H1 FY27 guidance reset will likely cut 25–35% (landing at ~₹980–1,200 Cr). Investors who acted on prior guidance face a material repricing; trust in management will need to be rebuilt through execution over 2–3 quarters.
The debate
What to watch next
1 · H1 FY27 earnings and guidance reset (expected Q3)
Management has deferred full-year guidance. Look for EBITDA reset to ₹1,000–1,200 Cr (vs prior ₹1,500–1,600 Cr), a 25–35% cut. If worse (>35% cut), stock could fall to ₹140–150. If better (<25% cut), expect relief rally to ₹190–210.
2 · ALMM 2 finalization (Dec 31, 2026)
Policy has been deferred twice already. If deferred a third time, C&I procurement pause continues and FY27 volume could undershoot. If finalized on schedule, expect 15 GW/year C&I demand unlock and DCR ramp acceleration in H2 FY27. This is a binary catalyst.
3 · Cell plant commissioning (Q4 FY27) and first wafer costs
Gangaikondam module on-time (June 29) proves execution. Cell plant commissioning will determine if in-house cell cost is competitive vs ₹4 cents/W landed price + 27.5% BCD for Chinese cells. If cell cost >₹5.5/W, margin accretion is lower than expected.
4 · DCR volume trajectory (expected to 2–2.5x quarterly from 76 MW base)
Q1 DCR was 76 MW (7.5% of volume). If Q2–Q3 see 150+ MW DCR, the ramp is on track. If base stays <100 MW/quarter, distribution and policy volatility are real headwinds. This will determine if FY27 EBITDA can exceed 9%.
The number to track from here
EBITDA per watt is the equity beta. Q1 delivered ₹1.25/Wp (₹126 Cr EBITDA / 1,006 MW). Historically, Vikram was ₹1.50–2.00/Wp. The 37% shortfall is the structural margin compression. If cell plant commissioning (Q4 FY27) and margin accretion begin lifting this metric toward ₹1.50/Wp by late FY28, the backward integration thesis is working and the stock re-rates higher. If it stays stuck at ₹1.25–1.35/Wp through FY28, oversupply and policy risk remain load-bearing, and further downside (to ₹120–140) is likely.
Vikram Solar delivered on volume and capex execution this quarter, but at the cost of a catastrophic margin collapse that makes a mockery of prior FY27 EBITDA guidance. The ₹1,500–1,600 Cr target is gone, replaced by a deferred H1 reset that will likely cut 25–35%.
The backward integration thesis — cell in Q4, wafer-ingot in FY29 — is structurally sound and worth a 2–3 year hold. But FY27 and FY28 margins are locked in by 210 GW of national oversupply. Pricing power will not return until consolidation reshuffles the market (2–3 years).
The stock's 53.88% drawdown from ATH is justified. Downside to ₹140–150 is possible if H1 guidance misses by >35%. Upside to ₹220–240 emerges only if cell margin accretion proves +2–3% in early FY28 and ALMM 2 finalizes on schedule.
Rating: Hold. Patience is rewarded on a 24-month horizon, but near-term (FY27) is structurally impaired. Wait for H1 FY27 guidance, ALMM 2 finalization (Dec 31), and cell plant commissioning (Q4 FY27) before reconsidering upside.
Vikram Solar Q1FY27: PAT crashes 85% YoY to ₹19.8 Cr despite 38% revenue growth
PAT -85.2% YoY · revenue +37.9% · margins compressing · miss vs street
₹1,563.09 Cr
+37.9% YoY
₹19.78 Cr
-85.2% YoY
1.26%
-10.5pp YoY
₹0.55
Vikram Solar's consolidated Q1FY27 print is a clear miss: PAT fell 85.2% YoY (and 82.1% QoQ) to ₹19.8 Cr even as revenue grew 37.9% YoY to ₹1,563.1 Cr (₹1,452.8 Cr in Q4FY26; ₹1,133.6 Cr a year ago). Analyst previews (Goodreturns) had modeled steeper revenue growth of ~52.6% YoY but a shallower PAT decline of ~-35.2% YoY with NPM near 12.4% — the actual print undershot both the top-line growth and the profitability bar, with NPM cratering to 1.27% versus 11.72% a year ago and 7.51% last quarter.
Q1 FY-2027 vs prior quarters
The compression sits squarely on the cost line: cost of materials consumed, net of the inventory build, rose to roughly 81% of revenue this quarter versus ~69% a year ago and ~72% last quarter, implying module realizations have not kept pace with input costs. EBITDA margin (OPM) nearly halved sequentially and more than halved YoY, falling to ~8.1% from 16.1% (QoQ) and 21.4% (YoY). Finance costs rose 53% YoY to ₹49.4 Cr and depreciation rose 91% YoY to ₹64.0 Cr as the ongoing capex ramp adds fixed costs ahead of the revenue scale needed to absorb them.
The stock went into the print at ₹173.96, down 5.3% over the past month of trading.
For context: revenue is at a 5-quarter high.
What the summary numbers don't show
Basic EPS fell to ₹0.55 (consolidated) from ₹4.21 YoY and ₹3.05 QoQ.
Management guides for significant volume growth in FY27 with expected production of approximately 8 gigawatts, projecting a 74% increase in EBITDA to INR 1,500-1,600 crores despite some near-term margin optimization. The company is executing a large-scale, multi-year capex plan focused on full backward integration into
— This quarter: missed
Management's May 2026 concall guided FY27 production of ~8GW and a 74% jump in full-year EBITDA to ₹1,500-1,600 Cr, while explicitly flagging "some near-term margin optimization." Q1's EBITDA of ~₹126 Cr annualizes to roughly a third of the low end of that target, so this quarter's margin dip is directionally consistent with that warning but larger in magnitude than "some" implies — the full-year target is now contingent on a sharp margin recovery over the remaining three quarters. The same board meeting approved raising the Gangaikondan (Tamil Nadu) wafer/ingot capacity from 6GW to 9GW at up to ₹5,589 Cr, timed to the ALMM-3 mandate effective June 2028 — a fresh capex commitment layered on top of an already-compressed quarter. No management press release accompanied this filing; the company's earnings call is scheduled for August 7, 2026.
W1
Whether FY27 EBITDA can still reach management's guided ₹1,500-1,600 Cr (74% growth) — Q1 EBITDA of ~₹126 Cr annualizes to roughly a third of that run-rate.
W2
Trajectory of the materials-to-revenue ratio in Q2 (currently ~81% vs ~69% YoY) as backward integration into cells/wafers progresses.
W3
Funding and progress of the newly expanded 9GW Gangaikondan capacity (~₹5,589 Cr capex) against management's stated net debt/equity ceiling of 1.5x.
No exceptional items in current or year-ago quarter; PAT decline is margin-driven (materials cost ~81% of revenue vs ~69% YoY) plus finance cost +53% YoY and depreciation +91% YoY from capex ramp; standalone PAT ₹18.7 Cr closely tracks consolidated ₹19.8 Cr, no material basis divergence; filed in ₹ million, converted to ₹ Crore (÷10); safeguard-duty (₹148.5 Cr) and disputed EPC receivable (₹52.8 Cr) items are balance-sheet contingencies, not P&L impacts this quarter.